Cargando…
EEG as a translational biomarker and outcome measure in fragile X syndrome
Targeted treatments for fragile X syndrome (FXS) have frequently failed to show efficacy in clinical testing, despite success at the preclinical stages. This has highlighted the need for more effective translational outcome measures. EEG differences observed in FXS, including exaggerated N1 ERP ampl...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786970/ https://www.ncbi.nlm.nih.gov/pubmed/35075104 http://dx.doi.org/10.1038/s41398-022-01796-2 |